Please login to the form below

Not currently logged in
Email:
Password:
Rare diseases

Companies developing rare disease treatments face several unique challenges when it comes to regulatory and reimbursement submissions.

The most pressing of these include the paucity of information on patient populations, disease progression and appropriate Clinical Outcome Assessments (COAs) as well as the challenges associated with collecting appropriate evidence in rare diseases. Alongside this is determining the needs for HTA and payer bodies to ensure a positive value assessment and reimbursement.

As well as these challenges, there are fundamental issues for clinical trial design that are magnified in rare diseases such as determining appropriate sample sizes and comparators and generating evidence to support selected endpoints.

On 22 March this PMLiVE webinar, in association with Adelphi Values, will use real-world examples to highlight the importance of evidence such as appropriate endpoints, including COAs, and comparators in rare diseases to support regulatory and reimbursement submissions. 

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics